palmitoylethanolamide.com.au
HomeResearchNaccari 2026

Palmitoylethanolamide in Human and Animal Obesity

Naccari C, Mancuso E, Di Paola ED, De Sarro G. Molecules. 2026;31(14):2524.

ReviewHumansDogsCats

Design
Review
Subjects
Narrative review with a stated database search
Dose used in the study
Not applicable
Duration
Not applicable
What was measured
The link between chronic inflammation and obesity in people and companion animals, current drug treatments, and the case for palmitoylethanolamide as an adjunct

What the authors reported

Given the inflammation-obesity link, the authors argue palmitoylethanolamide could be a strategy in human obesity, noting it is already sold as a veterinary food supplement.

Limits of this study

A review that proposes a use rather than reporting trials of it. The abstract cites no human weight-loss trial. This database holds only one small human metabolic study. Open access, MDPI.

Source

PubMed 42513202 · doi:10.3390/molecules31142524

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.